Shaibu plots to succeed Obaseki in 2024 — Ebea

The results of Phase I/II trial published on the 20th of July 2020 in the scientific journal, The Lancet, indicate no early safety concerns even as it induces strong immune responses in both parts of the immune system. According to the report, the vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted).

Read more at: https://www.vanguardngr.com/2020/07/oxford-coronavirus-vaccine-produces-strong-immune-response-study/

The results of Phase I/II trial published on the 20th of July 2020 in the scientific journal, The Lancet, indicate no early safety concerns even as it induces strong immune responses in both parts of the immune system. According to the report, the vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted).

Read more at: https://www.vanguardngr.com/2020/07/oxford-coronavirus-vaccine-produces-strong-immune-response-study/

The results of Phase I/II trial published on the 20th of July 2020 in the scientific journal, The Lancet, indicate no early safety concerns even as it induces strong immune responses in both parts of the immune system. According to the report, the vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted).

Read more at: https://www.vanguardngr.com/2020/07/oxford-coronavirus-vaccine-produces-strong-immune-response-

Former deputy Speaker of the Edo State House of Assembly, Festus Ebea, called on the people of Edo Central Senatorial District to vote for the APC candidate in the forth coming governorship election.

 He said contrary to promises being made by Governor Godwin Obaseki, his deputy, Comrade Philip Shaibu, is surely having a plot to takes over from his boss in 2024.

He said voting for Pastor Osagie Ize-Iyamu was the best bet for Edo Central to have a shot at the governorship seat.

In a chat with Vanguard, Ebea alleged that if Obaseki wins his second term, he would hand over to Shaibu in their third year and then proceed to the Senate and pave the way for Shaibu to begin a fresh term in 2024.

Ebea said: “I remember in 2012 when we were celebrating the victory of Comrade Adams Oshiomhole’s second term re-election. We, as colleagues, we were just so joyous and out of excitement he (Shaibu) said after Comrade, the next person that will take over from him will certainly hand over to him.

“And when you see the events playing out, especially within the executive sphere of Edo State, you will find out that the relationship that now exists between the Governor and Deputy Governor, is not borne out of anything other than to respect the wish of Philip Shaibu."

He described Ebea’s comments on the 2024 governorship election as sickening and unacceptable.

Shaibu: “My destiny is in the hands of God and it is only God that can determine the future. I don’t know the next position that God is taking me.I am not like Ebea that brags on his ability. I brag on God’s ability, which is my driving force. He should speak about himself. He should not speak for me.”

Former Deputy Speaker of the Edo State House of Assembly, Festus Ebea, on Tuesday, called on the people of Edo Central Senatorial District to vote for All Progressives Congress, APC, and its candidate in the September 19 governorship election, saying contrary to promises being made by Governor Godwin Obaseki, his deputy, Comrade Philip Shaibu, is actually plotting to ensure he takes over from his boss in 2024.results of Phase I/II trial published on the 20th of July 2020 in the scientific journal, The Lancet, indicate no early safety concerns even as it induces strong immune responses in both parts of the immune system. According to the report, the vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted).

Read more at: https://www.vanguardngr.com/2020/07/oxford-coronavirus-vaccine-produces-strong-immune-response-study/

The results of Phase I/II trial published on the 20th of July 2020 in the scientific journal, The Lancet, indicate no early safety concerns even as it induces strong immune responses in both parts of the immune system. According to the report, the vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted).

Read more at: https://www.vanguardngr.com/2020/07/oxford-coronavirus-vaccine-produces-strong-immune-response-study/

The results of Phase I/II trial published on the 20th of July 2020 in the scientific journal, The Lancet, indicate no early safety concerns even as it induces strong immune responses in both parts of the immune system. According to the report, the vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted).

Read more at: https://www.vanguardngr.com/2020/07/oxford-coronavirus-vaccine-produces-strong-immune-response-study/

The results of Phase I/II trial published on the 20th of July 2020 in the scientific journal, The Lancet, indicate no early safety concerns even as it induces strong immune responses in both parts of the immune system. According to the report, the vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted).

Read more at: https://www.vanguardngr.com/2020/07/oxford-coronavirus-vaccine-produces-strong-immune-response-study/

The results of Phase I/II trial published on the 20th of July 2020 in the scientific journal, The Lancet, indicate no early safety concerns even as it induces strong immune responses in both parts of the immune system. According to the report, the vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted).

Read more at: https://www.vanguardngr.com/2020/07/oxford-coronavirus-vaccine-produces-strong-immune-response-study/